News|Articles|May 15, 2026

NeurologyLive® Friday 5 — May 15, 2026

Listen
0:00 / 0:00

Key Takeaways

  • Abbott’s R&D perspective highlights DBS evolution via improved patient phenotyping, directional leads, closed-loop or sensing-enabled systems, and streamlined programming to personalize Parkinson disease therapy.
  • Advanced multimodal imaging is enabling stroke triage based on salvageable tissue rather than clock time, with telestroke networks extending expertise and accelerating reperfusion decisions.
SHOW MORE

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 15, 2026.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more or watch now buttons for more details and information about each highlight.

1: How Deep Brain Stimulation is Evolving Parkinson Disease

In a recent Q&A, Rebecca Wilkins, Divisional Vice President of R&D Neuromodulation at Abbott, discusses the evolving role of deep brain stimulation in Parkinson disease, including patient selection, newer DBS technologies, and integration with emerging therapies.

2: Advancing Stroke Imaging Through Tissue-Based Decision-Making: Rahul Chandra, MD

In a recent interview, Rahul Chandra, MD, medical director for telestroke at Allegheny Health Network, discussed how evolving imaging modalities may be reshaping stroke care in honor of Stroke Awareness Month. [WATCH TIME: 5 minutes]

3: High-Dose Nusinersen and the Future of SMA Treatment

In a recent interview, Thomas Crawford, MD, a pediatric neurologist at Johns Hopkins, discussed the FDA's recent approval of high-dose nusinersen for spinal muscular atrophy and SMA's evolving landscape of care.

4: NeuroVoices: Gus Alva, MD, DFAPA, on Potential Impact of Newly Approved AXS-05 for Alzheimer Disease Agitation

In our latest NeuroVoices Q&A, Gus Alva, MD, DFAPA, medical director of ATP Clinical Research, commented on the potential clinical impact of AXS-05 for agitation in Alzheimer disease, caregiver burden, and the evolving collaboration between neurology and psychiatry.

5: Highlighting Key Clinical and Research Trends From the 2026 AAN Annual Meeting

In a recent interview, H. E. Hinson, MD, MCR, FAAN, discussed how neurology is rapidly evolving toward interventional therapies, prevention-focused care, and adaptive trial designs, based on presentations from AAN 2026.

Which conversation stood out most to you in this week’s NeurologyLive Friday Five?

Q&A: Rebecca Wilkins
Video: Rahul Chandra, MD
Q&A: Thomas Crawford, MD
Q&A: Gus Alva, MD, DFAPA
Q&A: H. E. Hinson, MD, MCR, FAAN

Don’t have time to read or watch a full video interview? Click here to check out our shorts!


Latest CME